Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

Background: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/-tide treatment naïve chronic hepatitis B patient (CHB) at weeks 48, 96, and 1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 2006-10, Vol.55 (10), p.1488-1495
Hauptverfasser:	Yeon, J E, Yoo, W, Hong, S P, Chang, Y J, Yu, S K, Kim, J H, Seo, Y S, Chung, H J, Moon, M S, Kim, S-O, Byun, K S, Lee, C H
Format:	Artikel
Sprache:	eng
Schlagworte:	adefovir dipivoxil Adenine - analogs & derivatives Adenine - therapeutic use Adult ADV Antibiotics. Antiinfectious agents. Antiparasitic agents Antigens Antiviral agents Biological and medical sciences CHB chronic hepatitis B compensated liver cirrhosis decompensated liver cirrhosis Deoxyribonucleic acid DNA DNA polymerase drug resistance Drug Resistance, Viral - genetics Female Gastroenterology. Liver. Pancreas. Abdomen Genotype HBeAg HBV Hepatitis hepatitis B e antigen Hepatitis B virus Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - genetics Human viral diseases Humans Infectious diseases Interferon lamivudine Lamivudine - therapeutic use LC-c LC-d Liver cirrhosis LMV Male Medical sciences Middle Aged Mutation Mutation - genetics Organophosphonates - therapeutic use Patients PCR Pharmacology. Drug treatments Phenotype polymerase chain reaction Real time restriction fragment mass polymorphism Retrospective Studies Reverse Transcriptase Inhibitors - therapeutic use reverse transcription RFMP Viral diseases Viral hepatitis Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!